Optimizing taxane use in MBC in the emerging era of targeted chemotherapy

Critical Reviews in Oncology/Hematology

Volumn 85, Issue 3, 2013, Pages 315-331

  von Minckwitz, G ^a   Martin, M ^b   Wilson, G ^c   Alba, E ^d   Schmidt, M ^e   Biganzoli, L ^f   Awada, A ^g  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f ISTITUTO TOSCANO TUMORI   (Italy)

^g JULES BORDET INSTITUTE   (Belgium)

Author keywords

Biomarkers; Breast cancer; Metastatic; Paclitaxel albumin; SPARC; Taxane

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CAVEOLIN 1; CREMOPHOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; KI 67 ANTIGEN; METHOTREXATE; OSTEONECTIN; PACLITAXEL; POLYSORBATE 80; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN; TAU PROTEIN; TAXANE DERIVATIVE; TESETAXEL; TRANSDUCIN; TRASTUZUMAB;

ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DIARRHEA; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SOLUBILITY; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; HUMAN; INFECTION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT DURATION; TRIPLE NEGATIVE BREAST CANCER; VOMITING; XERODERMA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; TAXOIDS; TREATMENT OUTCOME;

EID: 84873525763     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.09.009     Document Type: Review

References (138)

1. Beslija S., Bonneterre J., Burstein H.J., et al. Third consensus on medical treatment of metastatic breast cancer. Annals of Oncology 2009, 20:1771-1785.
2. Cardoso F., Fallowfield L., Costa A., Castiglione M., Senkus E. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2011, 22(Suppl. 6):vi25-vi30.
3. NCCN clinical practice guidelines in oncology: breast cancer version 2.2011 2011, Available at: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf [accessed 30.06.2011].
4. Langer C.J., O'Byrne K.J., Socinski M.A., et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. Journal of Thoracic Oncology 2008, 3:623-630.
5. O'Brien M.E., Socinski M.A., Popovich A.Y., et al. Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. Journal of Thoracic Oncology 2008, 3:728-734.
6. Paz-Ares L., Ross H., O'Brien M., et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. British Journal of Cancer 2008, 98:1608-1613.
7. Today M.N. Phase 3 pivotal trial of TOCOSOL(R) paclitaxel does not meet primary endpoint 2007, Available at: http://www.medicalnewstoday.com/releases/83574.php [accessed 21.10.2011].
8. Montana M., Ducros C., Verhaeghe P., Terme T., Vanelle P., Rathelot P. Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers. Journal of Chemotherapy 2011, 23:59-66.
9. Desai N. Nab technology: a drug delivery platform utilising endothelial gp60 receptor-based transport and tumour-derived SPARC for targeting. Drug Delivery Report 2007/2008;16th Edition:37-41.
10. Guarneri V., Dieci M.V., Conte P. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. Expert Opinion on Pharmacotherapy 2012, 13:395-406.
11. Ribeiro J.T., Macedo L.T., Curigliano G., et al. Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?. Annals of Oncology 2012, 23:547-555.
12. Miele E., Spinelli G.P., Tomao F., Tomao S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. International Journal of Nanomedicine 2009, 4:99-105.
13. ten Tije A.J., Verweij J., Loos W.J., Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clinical Pharmacokinetics 2003, 42:665-685.
14. Gradishar W.J., Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. Journal of Clinical Oncology 2005, 23:7794-7803.
15. Adams J.D., Flora K.P., Goldspiel B.R., Wilson J.W., Arbuck S.G., Finley R. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. Journal of the National Cancer Institute Monographs 1993, 141-147.
16. Xiao H., Verdier-Pinard P., Fernandez-Fuentes N., et al. Insights into the mechanism of microtubule stabilization by Taxol. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:10166-10173.
17. Taxol® Summary of Product Characteristics. New York, NY, USA: Bristol-Myers Squibb; 2005.
18. Gianni L., Kearns C.M., Giani A., et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. Journal of Clinical Oncology 1995, 13:180-190.
19. Gelderblom H., Mross K., ten Tije A.J., et al. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. Journal of Clinical Oncology 2002, 20:574-581.
20. Winer E.P., Berry D.A., Woolf S., et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. Journal of Clinical Oncology 2004, 22:2061-2068.
21. Verweij J., Clavel M., Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Annals of Oncology 1994, 5:495-505.
22. Nabholtz J.M., Gelmon K., Bontenbal M., et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. Journal of Clinical Oncology 1996, 14:1858-1867.
23. Green M.C., Buzdar A.U., Smith T., et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. Journal of Clinical Oncology 2005, 23:5983-5992.
24. Sparano J.A., Wang M., Martino S., et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. The New England Journal of Medicine 2008, 358:1663-1671.
25. Fountzilas G., Dafni U., Dimopoulos M.A., et al. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Research and Treatment 2009, 115:87-99.
26. Seidman A.D., Berry D., Cirrincione C., et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. Journal of Clinical Oncology 2008, 26:1642-1649.
27. Verrill M.W., Lee J., Cameron D.A., et al. Anglo-Celtic IV: first results of a UK National Cancer Research Network randomised phase 3 pharmacogenetic trial of weekly versus 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC). Journal of Clinical Oncology 2007, 25. [abstract LBA1005].
28. Gianni L., Munzone E., Capri G., et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. Journal of Clinical Oncology 1995, 13:2688-2699.
29. Piccart-Gebhart M.J., Burzykowski T., Buyse M., et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. Journal of Clinical Oncology 2008, 26:1980-1986.
30. Albain K.S., Nag S.M., Calderillo-Ruiz G., et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. Journal of Clinical Oncology 2008, 26:3950-3957.
31. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. The New England Journal of Medicine 2007, 357:2666-2676.
32. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England Journal of Medicine 2001, 344:783-792.
33. Robert N., Leyland-Jones B., Asmar L., et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. Journal of Clinical Oncology 2006, 24:2786-2792.
34. Bissery M.C., Guenard D., Gueritte-Voegelein F., Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Research 1991, 51:4845-4852.
35. Taxotere® Summary of Product Characteristics. Available at: [accessed 11.07.2011]. http://www.medicines.org.uk/EMC/medicine/23210/SPC/TAXOTERE+20+mg+1ml+and+80mg+4ml++and+160+mg+8ml+concentrate+for+solution+for+infusion/.
36. Bruno R., Sanderink G.J. Pharmacokinetics and metabolism of Taxotere (docetaxel). Cancer Surveys 1993, 17:305-313.
37. Clarke S.J., Rivory L.P. Clinical pharmacokinetics of docetaxel. Clinical Pharmacokinetics 1999, 36:99-114.
38. Bruno R., Hille D., Riva A., et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. Journal of Clinical Oncology 1998, 16:187-196.
39. Bruno R., Vivier N., Veyrat-Follet C., Montay G., Rhodes G.R. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Investigational New Drugs 2001, 19:163-169.
40. Aapro M. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group. Seminars in Oncology 1998, 25:7-11.
41. Jones S.E., Erban J., Overmoyer B., et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. Journal of Clinical Oncology 2005, 23:5542-5551.
42. Nabholtz J.M., Crown J. Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results. Seminars in Oncology 1998, 25:4-9.
43. Nabholtz J.M., Senn H.J., Bezwoda W.R., et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy 304 Study Group. Journal of Clinical Oncology 1999, 17:1413-1424.
44. Sjostrom J., Blomqvist C., Mouridsen H., et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. European Journal of Cancer 1999, 35:1194-1201.
45. Rivera E., Mejia J.A., Arun B.K., et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 2008, 112:1455-1461.
46. Schroder C.P., de Munck L., Westermann A.M., et al. Weekly docetaxel in metastatic breast cancer patients: no superior benefits compared to three-weekly docetaxel. European Journal of Cancer 2011, 47:1355-1362.
47. Stemmler H.J., Harbeck N., Groll de Rivera I., et al. Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer. Oncology 2010, 79:197-203.
48. Tabernero J., Climent M.A., Lluch A., et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Annals of Oncology 2004, 15:1358-1365.
49. Nabholtz J.M., Falkson C., Campos D., et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. Journal of Clinical Oncology 2003, 21:968-975.
50. O'Shaughnessy J., Miles D., Vukelja S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology 2002, 20:2812-2823.
51. Miles D.W., Chan A., Dirix L.Y., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of Clinical Oncology 2010, 28:3239-3247.
52. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. Journal of Clinical Oncology 2005, 23:4265-4274.
53. Valero V., Forbes J., Pegram M.D., et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. Journal of Clinical Oncology 2011, 29:149-156.
54. Harvey V., Mouridsen H., Semiglazov V., et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. Journal of Clinical Oncology 2006, 24:4963-4970.
55. Loibl S., Skacel T., Nekljudova V., et al. Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer - a pooled analysis. BMC Cancer 2011, 11:131.
56. Gennari A., Stockler M., Puntoni M., et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. Journal of Clinical Oncology 2011, 29:2144-2149.
57. Lodotra (prednisone) Summary of Product Characteristics. Available at: [accessed 24.10.2011]. http://www.medicines.org.uk/EMC/medicine/23778/SPC/Lodotra+1+mg%2c+2+mg+and+5+mg+modified-release+tablets/%23tableOfContents.
58. Neupogen (filgrastim) Summary of Product Characteristics. Available at: [accessed 24.10.2011]. http://www.medicines.org.uk/EMC/medicine/23294/SPC/Neupogen+30+MU+(0.3+mg+ml)+and+48+MU+(0.3+mg+ml).+Solution+for+injection/.
59. EMA. Abraxane European Assessment Report 2008. Available at: [accessed 24.10.2011]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000778/WC500020433.pdf.
60. EMA. Abraxane Summary of Product Characteristics; 2008. Available at: [accessed 11.07.2011]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000778/WC500020435.pdf.
61. Schnitzer J.E., Oh P. Antibodies to SPARC inhibit albumin binding to SPARC, gp60, and microvascular endothelium. American Journal of Physiology 1992, 263:H1872-H1879.
62. Desai N., Trieu V., Yao Z., et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clinical Cancer Research 2006, 12(4):1317-1324.
63. Pinilla S.M., Honrado E., Hardisson D., Benitez J., Palacios J. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Research and Treatment 2006, 99:85-90.
64. Savage K., Lambros M.B., Robertson D., et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clinical Cancer Research 2007, 13:90-101.
65. Altundag K., Bulut N., Dizdar O., Harputluoglu H. Albumin-bound paclitaxel, ABI-007 may show better efficacy than paclitaxel in basal-like breast cancers: association between caveolin-1 expression and ABI-007. Breast Cancer Research and Treatment 2006, 100:329-330.
66. Sage H., Johnson C., Bornstein P. Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. Journal of Biological Chemistry 1984, 259:3993-4007.
67. Lau C.P., Poon R.T., Cheung S.T., Yu W.C., Fan S.T. SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. Journal of Pathology 2006, 210:459-468.
68. Pen A., Moreno M.J., Martin J., Stanimirovic D.B. Molecular markers of extracellular matrix remodeling in glioblastoma vessels: microarray study of laser-captured glioblastoma vessels. Glia 2007, 55:559-572.
69. Turk N., Kusec R., Jaksic B., Turk Z. Humoral SPARC/osteonectin protein in plasma cell dyscrasias. Annals of Hematology 2005, 84:304-310.
70. Massi D., Franchi A., Borgognoni L., Reali U.M., Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Human Pathology 1999, 30:339-344.
71. Thomas R., True L.D., Bassuk J.A., Lange P.H., Vessella R.L. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clinical Cancer Research 2000, 6:1140-1149.
72. Chin D., Boyle G.M., Williams R.M., et al. Novel markers for poor prognosis in head and neck cancer. International Journal of Cancer 2005, 113:789-797.
73. Koukourakis M.I., Giatromanolaki A., Brekken R.A., et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Research 2003, 63:5376-5380.
74. Yamanaka M., Kanda K., Li N.C., et al. Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. Journal of Urology 2001, 166:2495-2499.
75. Sova P., Feng Q., Geiss G., et al. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiology, Biomarkers & Prevention 2006, 15:114-123.
76. Kato Y., Nagashima Y., Baba Y., et al. Expression of SPARC in tongue carcinoma of stage II is associated with poor prognosis: an immunohistochemical study of 86 cases. International Journal of Molecular Medicine 2005, 16:263-268.
77. Yamashita K., Upadhay S., Mimori K., Inoue H., Mori M. Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression. Cancer 2003, 97:2412-2419.
78. Watkins G., Douglas-Jones A., Bryce R., Mansel R.E., Jiang W.G. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2005, 72:267-272.
79. Framson P.E., Sage E.H. SPARC and tumor growth: where the seed meets the soil?. Journal of Cellular Biochemistry 2004, 92:679-690.
80. Hawkins M, Desai N, Soon-Shiong P. Rationale, preclinical support, and clinical proof-of-concept for formulating water-insoluble therapeutics as albumin-stabilized nanoparticles: experience with paclitaxel. Presented at AACR 2003: Poster 1189.
81. Celgene. Data on file; 2011.
82. Trieu V, Hwang J, Desai N. Nanoparticle albumin-bound (nab) technology may enhance antitumor activity via targeting of SPARC protein. Presented at New Targets and Delivery System for Cancer Diagnosis and Treatment (SKCC) 2007 [abstract 57].
83. Desai N., Trieu V., Damascelli B., Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Translational Oncology 2009, 2:59-64.
84. Von Hoff D.D., Ramanathan R., Borad M., et al. SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: a phase I/II study. Journal of Clinical Oncology 2009, 27(Suppl.). [abstract 4525].
85. Yardley D.A., Inhorn R., Daniel B., et al. Preliminary progression free survival and SPARC tumor correlatives from a phase II neoadjuvant trial of gemcitabine, epirubicin, and nab paclitaxel. Cancer Research 2008, 69(Suppl.). [abstract 5116].
86. Basu G., Van Vickle G., Ghazalpour A., et al. Frequency distribution of SPARC in triple-negative breast cancer patients. Journal of Clinical Oncology 2011, 29(Suppl. 27). [abstract 37].
87. Paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation, or ixabepilone with or without bevacizumab in treating patients with stage IIIC or stage IV breast cancer. Available at: [accessed 31.10.2011]. http://clinicaltrials.gov/ct2/show/NCT00785291%3Fterm=40502%26intr=abraxane%26phase=2%26rank=1.
88. Phase III study of ABI-007 (albumin-bound paclitaxel) plus gemcitabine versus gemcitabine in metastatic adenocarcinoma of the pancreas. Available at: [accessed 31.10.2011]. http://clinicaltrials.gov/ct2/show/NCT00844649%3Fterm=pancreatic%26intr=abraxane%26phase=2%26rank=1.
89. A trial of ABI-007 versus dacarbazine in previously untreated patients with metastatic malignant melanoma. Available at: [accessed 31.10.2011]. http://clinicaltrials.gov/ct2/show/NCT00864253%3Fterm=SPARC%26intr=abraxane%26phase=2%26rank=1.
90. Study comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto). Available at: [accessed 29.07.2012]. http://clinicaltrials.gov/ct2/show/NCT01583426%3Fterm=NCT01583426%26rank=1.
91. Ibrahim N.K., Desai N., Legha S., et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clinical Cancer Research 2002, 8:1038-1044.
92. Nyman D.W., Campbell K.J., Hersh E., et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. Journal of Clinical Oncology 2005, 23:7785-7793.
93. Gardner E.R., Dahut W.L., Scripture C.D., et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clinical Cancer Research 2008, 14:4200-4205.
94. Sparreboom A., Scripture C.D., Trieu V., et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clinical Cancer Research 2005, 11:4136-4143.
95. Wang M., Thanou M. Targeting nanoparticles to cancer. Pharmacological Research 2010, 62:90-99.
96. Ibrahim N.K., Samuels B., Page R., et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. Journal of Clinical Oncology 2005, 23:6019-6026.
97. FDA. ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound); 2007. Available at: [accessed 07.07.2012]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021660s013lbl.pdf.
98. Gradishar W.J., Krasnojon D., Cheporov S., et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. Journal of Clinical Oncology 2009, 27:3611-3619.
99. Gradishar W.J., Krasnojon D., Cheporov S.V., et al. Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): final overall survival (OS) analysis of a randomized phase II trial. Journal of Clinical Oncology 2011, 29(Suppl.). [abstract 275].
100. Gradishar W.J., Krasnojon D., Cheporov S., et al. Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. Clinical Breast Cancer 2012, Jun 22 [Epub ahead of print].
101. Rugo H.S., Barry W.T., Moreno-Aspitia A., et al. CALGB 40502/NCCTG N063H: randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). Journal of Clinical Oncology 2012, 30(Suppl.). [abstract CRA1002].
102. Chirgwin J., Chua S.L. Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review. Breast 2011, 20:394-406.
103. Conlin A.K., Seidman A.D., Bach A., et al. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clinical Breast Cancer 2010, 10:281-287.
104. Northfelt D.W., Dueck A.C., Flynn T.P., et al. Phase II trial combining nab-paclitaxel (NP), gemcitabine (G), and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735. Journal of Clinical Oncology 2011, 29(Suppl.). [abstract 1126].
105. Roy V., LaPlant B.R., Gross G.G., Bane C.L., Palmieri F.M. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Annals of Oncology 2009, 20:449-453.
106. Somer B.G., Schwartzberg L.S., Arena F., Epperson A., Fu D., Fortner B.V. Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX))+capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC). Journal of Clinical Oncology 2007, 25(Suppl.). [abstract 1053].
107. Lobo C., Lopes G., Baez O., et al. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment 2010, 123:427-435.
108. Danso M.A., Blum J.L., Robert N.J., et al. Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer. Journal of Clinical Oncology 2008, 26(Suppl.). [abstract 1075].
109. Conlin A.K., Hudis C.A., Bach A., et al. Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC). Journal of Clinical Oncology 2009, 27(Suppl.). [abstract 1006].
110. Mirtsching B., Cosgriff T., Harker G., Keaton M., Chidiac T., Min M. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer. Clinical Breast Cancer 2011, 11:121-128.
111. Biganzoli L., Licitra S., Moretti E., Pestrin M., Zafarana E., Di Leo A. Taxanes in the elderly: can we gain as much and be less toxic?. Critical Reviews in Oncology/Hematology 2009, 70:262-271.
112. Taxol prescribing information. Available at: [accessed 02.11.2011]. http://packageinserts.bms.com/pi/pi_taxol.pdf.
113. Aapro M., Tjulandin S., Bhar P., Gradishar W. Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post hoc analysis. Breast 2011, 20:468-474.
114. Von Minckwitz G. ICE II: an investigational randomized phase II study on epirubicin (E) plus cyclophospamide (C) (or CMF) versus nab-paclitaxel plus capecitabine (PX) as adjuvant chemotherapy for elderly nonfrail patients with an increased risk for relapse of a primary carcinoma of the breast. Journal of Clinical Oncology 2010, 28(15s Suppl.). Group. obotGB, [abstract TPS104].
115. Palmieri C., Krell J., James C.R., et al. Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nature Reviews Clinical Oncology 2010, 7:561-574.
116. Blum J.L., Savin M.A., Edelman G., et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clinical Breast Cancer 2007, 7:850-856.
117. Nab-paclitaxel in metastatic breast cancer patients failing solvent based taxane (Tiffany). Available at: [accessed 02.11.2011]. http://clinicaltrials.gov/ct2/show/NCT01416558%3Fterm=tiffany%26intr=Abraxane%26rank=1.
118. Chang H.R., Glaspy J., Allison M.A., et al. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer 2011, 116:4227-4237.
119. von Minckwitz G., Untch M., Nuesch E., et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Research and Treatment 2011, 125(1):145-156.
120. O'Connor P.M., Jackman J., Bae I., et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Research 1997, 57:4285-4300.
121. Rouzier R., Rajan R., Wagner P., et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:8315-8320.
122. Di Leo A., Tanner M., Desmedt C., et al. p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Annals of Oncology 2007, 18:997-1003.
123. Bonnefoi H., Piccart M., Bogaerts J., et al. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncology 2011, 12:527-539.
124. Pusztai L., Jeong J.H., Gong Y., et al. Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. Journal of Clinical Oncology 2009, 27:4287-4292.
125. Bode C., Trojan L., Weiss C., et al. Paclitaxel encapsulated in cationic liposomes: a new option for neovascular targeting for the treatment of prostate cancer. Oncology Reports 2009, 22:321-326.
126. Awada A., Bondarenko I.N., Tarasova O., et al. Results of the first randomized phase II study of cationic liposomal paclitaxel (EndoTAGTM-1) targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). Annals of Oncology 2010, 21(Suppl. 8):viii5.
127. Shionoya M., Jimbo T., Kitagawa M., Soga T., Tohgo A. DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Science 2003, 94:459-466.
128. Potential new drug targets against hormone-dependent breast cancer identified. Expert Review of Anticancer Therapy 2008, 8:507.
129. Rhee J.M., Lee F., Saif M.W., et al. Phase II trial of DJ-927 as a second-line treatment for colorectal cancer demonstrates objective responses. Journal of Clinical Oncology 2005, 23(16S Suppl.). [abstract 3654].
130. Saif M.W., Sarantopoulos J., Patnaik A., Tolcher A.W., Takimoto C., Beeram M. Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 2011, 68:1565-1573.
131. Genta. Available at: [accessed 04.11.2011]. http://www.genta.com/Products_and_Pipeline/Tesetaxel/Clinical_Development.html.
132. Tesetaxel as first-line therapy for metastatic breast cancer. Available at: [accessed 04.11.2011]. http://clinicaltrials.gov/ct2/show/NCT01221870%3Fterm=tesetaxel%26rank=3.
133. Kulkarni S.A., Hicks D.G., Watroba N.L., et al. TLE3 as a candidate biomarker of response to taxane therapy. Breast Cancer Research 2009, 11:R17.
134. Dowsett M., Dunbier A.K. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clinical Cancer Research 2008, 14:8019-8026.
135. Chang J., Ormerod M., Powles T.J., Allred D.C., Ashley S.E., Dowsett M. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000, 89:2145-2152.
136. Faneyte I.F., Schrama J.G., Peterse J.L., Remijnse P.L., Rodenhuis S., van de Vijver M.J. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. British Journal of Cancer 2003, 88:406-412.
137. Kadra G., Finetti P., Toiron Y., et al. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents. Breast Cancer Research and Treatment 2011, Jul 27 [Epub ahead of print].
138. Petit T., Wilt M., Velten M., et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. European Journal of Cancer 2004, 40:205-211.